NeoGenomics reimbursement rates could rebound, says Roth CapitalRoth Capital expects reimbursement rates for NeoGenomics' tests to rebound in 2H15, since the firm believes, based on data, that most labs are probably performing the tests below costs. The firm keeps a $7 price target and Buy rating on NeoGenomics.